Ledningen kommer att ge en uppdatering om företagets pipeline baserad på Curasights egenutvecklade uPAR theranostics-plattform, som syftar till att förbättra diagnos och behandling av vissa typer av cancer, inklusive prostatacancer och hjärncancer. Presentationen kommer också att lyfta fram viktiga milstolpar på kort sikt för både detta och nästa år. Presentationen på Dansk Aktionærforening InvestorDagen äger rum 10:30 - 10:55 (CET), måndag 17 november 2025. En inspelning av webbsändningen kommer att finnas tillgänglig på Curasights webbplats efter evenemanget. För mer information om Curasight kan man kontakta Ulrich Krasilnikoff, VD, via telefon eller e-post.

Curasight is advancing its uTRACE® program, a non-invasive imaging tool for prostate cancer diagnosis and risk assessment, through a Phase 2 study in collaboration with Curium Inc. This partnership could bring Curasight up to USD 70 million in milestone payments and royalties upon commercialization. CEO Ulrich Krasilnikoff expressed satisfaction with the program's progress, expecting recruitment completion by mid-2026. Additionally, Curasight plans to start a Phase 1 trial for its therapeutic platform uTREAT® in brain cancer. The Phase 2 trial for uTRACE® involves using a PET tracer to assess tumor aggressiveness in prostate cancer patients under active surveillance, aiming to improve patient outcomes by distinguishing between indolent and aggressive diseases. Curasight's theranostic platform uses uPAR-targeting peptides for both imaging and therapy, relevant to most solid tumors.

Curasight har meddelat att de har fått ett nytt amerikanskt patent för sin diagnostiska plattform uTRACE®, vilket stärker skyddet för deras teknologi och förlänger plattformens patenttid. Detta bidrar till deras pågående prostatacancerprogram med Curium och potentiella framtida utvecklingar av uTRACE för andra cancerindikationer. Curasights theranostiska plattform kombinerar diagnostik och terapi genom att använda uPAR-målade peptider märkta med radioisotoper för antingen avbildning (uTRACE®) eller radioligandterapi (uTREAT®). Plattformen riktar in sig på uPAR, en markör för canceraggressivitet, som uttrycks i de flesta solida tumörer. För mer information kan man kontakta Curasights VD, Ulrich Krasilnikoff.

Lars Trolle, som är vice ordförande i styrelsen, har sålt 50,000 aktier till ett pris av 226,210.10 DKK. Efter försäljningen har han totalt 591,510 aktier i Curasight A/S. För mer information om Curasight kan man kontakta företagets VD, Ulrich Krasilnikoff.

Curasight's CEO, Ulrich Krasilnikoff, reported that in the second quarter of 2025, the company secured approximately DKK 65 million through new capital and loans. This funding will support their theranostic approach using radiopharmaceuticals to improve cancer diagnosis and treatment. The financial boost will help advance their phase II trial for the uTRACE® diagnostic platform in prostate cancer and the phase I trial for uTREAT® in glioblastoma, which has received regulatory approval to begin. For Q2 2025, Curasight reported a gross loss of kDKK -17,700, an operating loss of kDKK -19,011, a loss before tax of kDKK -20,579, and a loss for the period of kDKK -19,204. Total assets were kDKK 44,783, with an equity ratio of 67.6%, and earnings per share of DKK -0.43. For the first half of 2025, the gross loss was kDKK -22,399, operating loss was kDKK -25,220, loss before tax was kDKK -27,158, and loss for the period was kDKK -24,408. Total assets remained at kDKK 44,783, with an equity ratio of 67.6%, and earnings per share of DKK -0.54. These figures are compared to the same period in 2024, shown in parentheses. For further information, contact Ulrich Krasilnikoff.

Curasight is advancing its theranostic strategy for cancer diagnosis and treatment with a Phase 1 trial expected to start dosing patients by the end of the year. The company is now in clinical development with both its diagnostic platform, uTRACE, and therapeutic platform, uTREAT. The trial will explore uTREAT as a targeted radiopharmaceutical therapy for glioblastoma patients, informed by previous research and expert discussions. Curasight's uPAR platform, combining uTRACE and uTREAT, aims to improve diagnosis and treatment of uPAR-expressing cancers. Glioblastoma, a high-grade glioma, has a poor prognosis with a high unmet medical need for effective treatments. uTREAT could potentially reduce reliance on external beam radiation, minimizing side effects by targeting tumor tissue more specifically.